CELCUITY INC(NASDAQ:CELC) stock News

CELC Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Celcuity Inc.

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

17 days ago - By: Celcuity Inc.

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

a month ago - By: Celcuity Inc.

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program

a month ago - By: The Motley Fool

Celcuity Q2 Results Highlight Cash Surge

a month ago - By: The Motley Fool

Celcuity (CELC) Q2 2025 Earnings Call Transcript

a month ago - By: Benzinga

Insights into Celcuity's Upcoming Earnings

a month ago - By: Celcuity Inc.

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Benzinga - Mentions: BTCM DE TIC DFLI ...

Earnings Scheduled For August 14, 2025

2 months ago - By: Celcuity Inc.

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

2 months ago - By: Celcuity Inc.

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

2 months ago - By: Yahoo Finance - Mentions: TSLA MSFT

Up 215% YTD, Should You Grab This Growth Stock Before It’s Too Late?

2 months ago - By: Yahoo Finance

Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial

2 months ago - By: Celcuity Inc.

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

2 months ago - By: Stocktwits - Mentions: IWMW VTWG

This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why

2 months ago - By: Celcuity Inc.

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

2 months ago - By: Celcuity Inc.

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

2 months ago - By: Celcuity Inc.

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

2 months ago - By: Celcuity Inc.

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

3 months ago - By: Celcuity Inc.

CELCUITY INC (CELC) Stock News

CELC Latest News, Press Relases and Analysis

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program

Celcuity Q2 Results Highlight Cash Surge

Celcuity (CELC) Q2 2025 Earnings Call Transcript

Insights into Celcuity's Upcoming Earnings

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For August 14, 2025

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Up 215% YTD, Should You Grab This Growth Stock Before It’s Too Late?

Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib